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i 
Abstract 
 
During my four months with the Tennessee Emerging Infections Program (EIP), I was able to 
consistently grow and apply my knowledge of public health.  Vanderbilt University Medical 
Center was an exceptional place to carry out my Master of Public Health field experience.  I was 
not only exposed to public health in the areas of epidemiology and surveillance, but I also gained 
valuable experience regarding public health activities performed within a hospital setting.  The 
Infectious Disease physicians, the Emerging Infections Program staff, and all of the Health 
Policy staff members and students were beyond supportive during my time at Vanderbilt.  
Through my field experience and my capstone project, I was able to learn specific surveillance 
methods, extract patient information from medical charts and forms, navigate through pertinent 
databases, and properly gain informed consent from patients.   
I completed a primary project and several minor projects during my time at Vanderbilt.  My 
minor projects consisted of data entry for the surveillance of non-invasive pneumococcal 
pneumonia (SNiPP) study, data cleaning/auditing for the pneumococcal carriage study, and 
additional tasks with each team in EIP.  My capstone project involved the gram-positive 
bacterium Streptococcus pneumoniae.  This pathogen, also known as pneumococcus, causes 
acute bacterial infections and can easily become life threatening.  During this project, I extracted 
medical information from medical records and databases to conduct a descriptive statistic 
analysis on Streptococcus pneumoniae.  The purpose of my project was to evaluate cases of 
invasive disease, and to investigate underlying conditions and populations that had invasive 
pneumococcal disease (IPD) due to lack of vaccination.    
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Chapter 1: Field Experience-Emerging Infections Program, 
Nashville, TN 
 
In 1995, the Centers for Disease Control and Prevention (CDC) established the Emerging 
Infections Program (EIP) in response to the growing population, an increase in poverty, and the 
heightened international travels.  The EIP is a network of state health departments and 
collaborators such as, public health and clinical laboratories, state and federal agencies, academic 
establishments, and healthcare providers.  This program is a resource for surveillance, control, 
and prevention of infectious diseases (Centers for Disease Control and Prevention, 1994). Box 
1.1 shows the objectives of the Emerging Infections Program.    
1
                                                          
Box 1.1. Objectives of the Emerging Infections Program (Centers for Disease Control and 
Prevention, 1994)  
 
• Surveillance and Response
•Detect, investigate, and monitor emerging pathogens, 
the diseases they cause, and the factors influencing 
their emergence. 
Goal 1:
• Applied Research
•Use of laboratory science and epidemiology to 
optimize public health practice. 
Goal 2:
• Infrastructure and Training
•Strengthen public health infrastructures to support 
surveillance and research and to implement 
prevention and control programs. 
Goal 3:
• Prevention and Control 
•Ensure prompt implementation of prevention 
strategies and enhance communication of public 
health information about emerging diseases. 
Goal 4:
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Currently there are ten EIP sites in the states of California, Colorado, Connecticut, Georgia, 
Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee.   
The EIP is divided into four areas of concern consisting of invasive bacterial diseases, food-
borne illnesses, healthcare associated infections (HAI), and influenza.  Within the invasive 
bacterial diseases area, there is the Active Bacterial Core Surveillance (ABCs) program, which 
focuses on the epidemiology and surveillance of invasive bacterial diseases.  The invasive 
bacterial pathogens currently under surveillance include: Group A Streptococcus (GAS), Group 
B Streptococcus (GBS), Haemophilus influenza, Neisseria meningitidis, Streptococcus 
pneumoniae, and Methicillin-Resistant Staphylococcus aureus (MRSA).  Nationwide there are 
approximately 39 million people under ABC surveillance (Centers for Disease Control and 
Prevention, 2017).   
The FoodNet segment of EIP is a collaboration project of the CDC, the ten EIP sites, the USDA, 
and the FDA.  The project entails active surveillance of the pathogens, Salmonella, Shigella, 
Campylobacter, Shiga-toxin producing Escherichia coli, Listeria, Yersinia, Vibrio, 
Cryptosporidium, and Cyclospora.  Well over 15% of the United States population falls within 
the FoodNet surveillance catchment area (Centers for Disease Control and Prevention, 2017).   
The Healthcare Associated Infections-Community Interface (HAIC) program carries out active 
surveillance healthcare associated infections (HAI) such as, Clostridium difficile and other multi-
drug resistant gram-negative bacteria (Centers for Disease Control and Prevention, 2017).   In 
addition to this, the Influenza Hospitalization Surveillance Network (Flu-Surv Net) utilizes 
surveillance data to evaluate the severity of influenza outbreaks and to assess the effectiveness of 
influenza vaccines.  Furthermore, EIP also conducts smaller projects that involve tick-borne 
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diseases (TickNet) and Human Papillomavirus (HPV-IMPACT) (Centers for Disease Control 
and Prevention, 2017).    
The Tennessee Emerging Infections Program (TEIP) has a close relationship with over 130 
statewide laboratories, and collaborates with Vanderbilt Medical Center, the Tennessee 
Department of Health (TDH), as well as other institutions (Tennessee Department of Health, 
2017).  TEIP activities are carried out in all 95 counties, covering a population of 6.5 million 
(Tennessee Department of Health, 2017). During my time with EIP, I had the privilege to not 
only work with an amazing team at Vanderbilt Medical Center, but I was also able to participate 
in events and weekly surveillance meetings at the Communicable and Environmental Diseases 
and Emergency Preparedness (CEDEP) at TDH.     
Tennessee Emerging Infections Program-Vanderbilt Medical Center 
Projects 
 
The Tennessee Emerging Infections Program participates in three main projects: Active Bacterial 
Core Surveillance, Flu-Surv NET, and the HPV-IMPACT Project.  Additionally, minor 
programs, TickNET and HAIC, are also conducted onsite.  While the EIP team is closely 
intertwined, all personnel are appointed specific projects and tasks.  During my first few weeks 
at Vanderbilt, I was able to shadow all teams within EIP.  Although my major and minor project 
fell within the ABCs project, I had the opportunity to learn about the additional programs, Flu-
Surv NET and HPV IMPACT.   
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Active Bacterial Core Surveillance  
For my capstone project, I used ABCs protocols as well as descriptive statistics to understand 
and highlight knowledge of these specific invasive bacterial diseases, which will be explained in 
Chapter 4. 
SNiPP: 
The Surveillance for non-invasive pneumococcal pneumonia (SNiPP) is part of the ABCs 
program.  Pneumococcal pneumonia is a common bacterial complication of influenza and causes 
an estimated 400,000 hospitalizations within the United States each year (Centers for Disease 
Control and Prevention, 2015).  As a minor project, I assisted in data entry for the SNiPP project, 
which will be described in Chapter 3.   
Streptococcus pneumoniae: 
Among the multiple bacteria that fall within the ABCs category, Streptococcus pneumoniae is a 
gram-positive organism that has recently become a hot topic in the media and healthcare fields.  
Major clinical conditions of pneumococcal disease are pneumonia, meningitis, and bacteremia 
(Centers for Disease Control and Prevention, 2015).  While adults 65 years and older are at risk 
for pneumococcal disease, adults and children with immunosuppressant conditions are at the 
highest risk of infection (Musher et al, 2015).  Some studies suggest that children with 
immunosuppressant illnesses, such as human immunodeficiency virus (HIV) and sickle cell 
disease, are 50 times more likely to become infected with an invasive disease (Centers for 
Disease Control and Prevention, 2015).  More so, the rate of invasive bacterial disease in adults 
with HIV infection is estimated to be 174 per 100,000 people (Centers for Disease Control and 
Prevention, 2015).  Consequently, CDC recommends the routine vaccination of adults that are ≥ 
65 years and/or those with underlying conditions (Centers for Disease Control and Prevention, 
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2010).  As my primary project, I evaluated populations that had IPD due to lack of vaccinations, 
which will be discussed further in Chapter 4.  
Flu-Surv NET 
The TEIP has been involved in influenza surveillance, Flu-Surv NET, since 2003.  Influenza is 
responsible for more than 200,000 hospitalizations and 3,300 to 49,000 deaths annually in the 
United States (Centers for Disease Control and Prevention, 2017).  Yearly, the EIP sites collect 
critical influenza information that indicate the severity of that particular influenza season, 
determine mortality and morbidity rates, and also guide recommendations for future influenza 
seasons (i.e., vaccines and treatments). Adult and pediatric cases are included in the influenza 
surveillance, which is conducted in eight Tennessee counties, representing approximately 24% of 
the state’s population (Tennessee Department of Health, 2017).  All influenza data are sent to the 
CDC for the Flu View weekly surveillance report.  On the first day of my field experience, I was 
able to sit through a routine flu meeting with the EIP team.  During these meetings, influenza 
morbidity and mortality rates are discussed.  More so, team members would discuss unusual 
influenza cases, and brainstorm for future measures that might prove beneficial.  These measures 
included discussing severity of illness, recognizing high-risk conditions, and discussing influenza 
vaccination rates among the population in Tennessee.  I continued to partake in the numerous 
influenza meetings held throughout the 2016-2017 influenza season.   
HPV-IMPACT 
Human Papillomavirus (HPV) is the most common sexually transmitted disease (STDs) in the 
United States (Centers for Disease Control and Prevention, 2017).  Since 2008, Tennessee has 
been performing population-based surveillance for cervical dysplasia among females ≥ 18 years 
old that reside in Davidson County.  More so, population-based surveillance involves identifying 
all new cases of HPV in the Tennessee catchment areas. The HPV-IMPACT project was 
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developed as part of the CDC HPV-IMPACT project to evaluate the epidemiology of cervical 
cancer precursors in the vaccine era.  Currently, there are three licensed vaccines (Cervarix, 
Gardasil, and Gardasil 9) that prevent certain types of HPV (Centers for Disease Control and 
Prevention, 2017).   Initially, the HPV-IMPACT project caught my attention as a possible 
capstone project due to my interests in reproductive health. I was able to meet with the team and 
discuss their roles in the project, how the project impacted vaccine and treatment research, and 
also where Tennessee fell within the HPV vaccination rates.  Unfortunately, there was not an 
ongoing project for me to assist on at the time, but I continued to stay informed about the HPV-
IMPACT program during my time at Vanderbilt. 
Tennessee Department of Health 
 
My experience with the Tennessee Department of Health allowed me to grasp a profound 
knowledge of multiple aspects of public health.  The experience aided me in growing and 
applying my knowledge of public health that I have obtained thus far at Kansas State University. 
I was able to meet with multiple public health officials and then discuss their major roles in the 
health of the state. Additionally, I was able to attend weekly surveillance meetings at the 
Tennessee State Health Department, where I was informed of disease outbreaks and other health 
issues throughout the state.  
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Chapter 2: 2017 Data Entry for Surveillance for Non-Invasive 
Pneumococcal pneumonia (SNiPP) in ABCs 
Introduction 
Pneumococcal pneumonia is the most common form of pneumococcal disease in adults, and is 
known to follow influenza infection (Mccullers, 2006).  Influenza and pneumococcal diseases 
are two of the most common illnesses that affect humans today (Mccullers, 2006).  Bacterial 
infections following the influenza viruses are highly common in adults and children (Mccullers, 
2006).  Influenza viruses allow pneumococci to adhere and invade the host, predisposing the 
individual to infection (Mccullers, 2006).   Pneumococci account for approximately 36% of 
community-acquired pneumonia (Centers for Disease Control and Prevention, 2015).  Over 
900,000 adults are diagnosed with pneumococcal pneumonia each year in the United States.  
Although the case-fatality rate of pneumococcal pneumonia is fairly low, 5%-7%, it can become 
significantly higher in elderly adults (Centers for Disease Control and Prevention, 2015).  
Surveillance for non-invasive pneumococcal pneumonia started within the ABCs program in 
2013.  All possible cases of non-invasive pneumococcal pneumonia, within the catchment area, 
are submitted to EIP.  EIP thus keeps track of these cases and the patient information by the use 
of a database called REDCap.  Surveillance is conducted in hospitals that offer pneumococcal 
urine antigen tests (UATs). These particular hospitals within the catchment areas are located in 
Knox, as well as Davidson and surrounding counties.    
Although pneumonia can be diagnosed with clinical symptoms and radiological evidence, 
additional diagnostic tools can be used to provide an early recognition of the specific pathogen, 
and can thus lead to the appropriate antimicrobial therapy (Couturier, 2014).  Urine antigen tests 
are a rapid and efficient way to test for respiratory diseases, such as pneumococcal pneumonia 
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(Couturier, 2014).  Before the UAT debuted in 2003, blood cultures, sputum stain and cultures, 
serology, and other tests were used to diagnose pneumococcal illnesses (Couturier, 2014).  
Unfortunately, these previous diagnostic methods had several disadvantages, such as result time 
and other limitations regarding the anatomic location of the pathogen (Couturier, 2014).   
Likewise, the UAT capitalizes the concentration of antigens in the urine specimen of the patient; 
the specific antigens are detected using an enzyme-linked immunosorbent assay (ELISA) or a 
lateral flow assay (LFA) (Couturier, 2014).  An advantage to this specific test is that is can be 
conducted by the bedside and results can be ready in a minimum of fifteen minutes (Couturier, 
2014).  More so, the UAT is FDA approved and can detect 100% of the 23 most important 
serotypes of pneumococcus (Couturier, 2014).    
 In 2014, the Advisory Committee on Immunization Practices (ACIP) recommended the routine 
use of the vaccine series 13-valent pneumococcal conjugate vaccine (PCV 13) and the 23-valent-
pneumococcal-polysaccharide vaccine (PPSV 23) (Centers for Disease Control and Prevention, 
2015).  EIP proposed to use population-based surveillance for SNiPP starting in 2013, before the 
recommended use of the vaccine series, PCV 13 and PPSV 23.  Through a surveillance program, 
disease burden was recorded in the years following the ACIP recommendation.  During my field 
study, I was able to enter pertinent medical information into the database for the SNiPP project.  
Objective 
The objective of this data entry was to properly transfer patient medical information from the 
hard copy of the case report form (CRF) to the electronic form entry.  The results from the data 
entry are used to provide population-based estimates that are easily transmitted to the CDC for 
future studies and revisions.   
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Methods 
Database: 
SNiPP data is collected from over ten counties in Tennessee.  Healthcare facilities, including 
hospitals and clinics, report the non-invasive pneumococcal pneumonia cases to Tennessee EIP 
each week.   This data is then submitted to a database known as REDCap.  REDCap (Research 
Electronic Data Capture) is a software solution to develop and manage online surveys and 
databases.  REDCap was established by Vanderbilt University, and over 2,000 institutional 
partners in 100 countries have taken advantage of this software.  In 2016, the TN EIP began 
transferring their data from Microsoft Access to a REDCap platform.  The TN EIP has recently 
finished transferring all ABCs data to REDCap, and has thus begun the data transfer of other 
programs.  REDCap eliminates the manual transmission of data to CDC and allows for a much 
simpler method of data extraction.    
Data Entry: 
As one of my minor projects with EIP, I was able to enter SNiPP data into REDCap.  The data 
entered consisted of negative SNiPP cases, meaning these patients were tested for non-invasive 
pneumococcal pneumonia via a UAT (urine antigen test) but tested negative. I was responsible 
for entering information regarding the full name, medical identification number, date of birth (if 
applicable), the hospital identification code, and the result of the UAT.  Figure 3.1 shows an 
example of the database entry within REDCap Patient Tracker.   
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Results 
During the course of my field experience, I entered over 1,000 negative UAT cases into REDCap 
for the SNiPP program.  The catchment hospitals transferred all possible UAT cases to EIP each 
week, allowing me to submit the UAT negatives into the database each day.  Additional EIP 
personnel submitted the positive cases into the database, REDCap.  There are now approximately 
7,400 negative UATs cases in the REDCap Patient Tracker.  This allowed for the EIP to move 
forward transmitting these data to the CDC, and conducting further submission and research 
within the SNiPP program. 
Discussion 
Pneumococcal pneumonia is a notably common infection nationwide.  As such, surveillance is 
critical so that evaluation of the disease, treatments, and vaccinations can be implemented.  
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Likewise, it is just as important to enter the negative cases, as it is the positive cases, to ensure 
proper population-based estimates of the disease.  More so, the EIP is analyzing the proportions 
of pneumonia hospitalizations in those hospitals that perform the UATs and those that do not. 
This will enlighten the CDC on the efficacy of the UAT at diagnosing pneumococcal pneumonia. 
I was able to assist in submitting these data into the database at a timely manner, so that the EIP 
team and the CDC can carry out these necessary studies.   
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Chapter 3: High Risk Conditions and Vaccination Gaps in Invasive 
Pneumococcal Disease Cases in Tennessee, 2011-2016 
 
Introduction 
The purpose of the Active Bacterial Core Surveillance (ABCs) group is to determine incidence 
and epidemiological patterns of invasive disease that are due to Haemophilus influenza, 
Neisseria meningitidis, Group A Streptococcus (GAS), Group B Streptococcus (GBS), and 
Streptococcus pneumoniae.  Among these bacteria, Streptococcus pneumoniae, a gram-positive 
anaerobic organism, is a public health concern with its potential to be life threatening.  Also 
known as pneumococcus, Pasteur first isolated the organisms in 1881 from the saliva of a rabies 
positive patient (Baxter, 2016).  Following the discovery of pneumococci, studies involving the 
findings of several serotypes and possible vaccination treatments were conducted.  As of 2011, 
92 serotypes have been documented.  These studies also suggest that pneumococci can be 
encapsulated, meaning their surface is formed from complex polysaccharides.  The capsule, as 
well as a recently identified protein, provides resistance of phagocytosis allowing the 
pneumococci to escape (Henriques-Normark, 2013). These encapsulated organisms are 
antigenic, and also hold the key to classifying pneumococci serotypes (Centers for Disease 
Control and Prevention, 2015).  
Although pneumococci are normal inhabitants of the respiratory tract and can be extracted from 
the nasopharynx of 5% to 90% of healthy individuals, a significant number of serotypes have 
been shown to cause serious disease (Centers for Disease Control and Prevention, 2015).  In 
pediatric cases, serotypes 6A, 14, 19F, 23F are heavily prevalent and result in 60% of all 
infections.  However, in adults, serotypes 6A, 3, and 19F account for only 31% of all infections 
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(Henriques-Normark, 2013).  Major clinical illnesses associated with pneumococcus include: 
pneumonia, bacteremia, meningitis, as well as minor conditions such as otitis media and 
sinusitis.  These infections can be considered invasive, meaning the bacteria invade parts of the 
body that are normally sterile.  Invasive pneumococcal bacteria can cause serious acute illnesses, 
such as pneumococcus in the bloodstream (bacteremia), meningitis, and in some cases death 
(Centers for Disease Control and Prevention, 2015).  Invasive pneumococcal disease (IPD) is 
responsible for over 12,000 bacteremia cases, 50% of meningitis cases, and approximately 
22,000 deaths in the United States every year (Centers for Disease Control and Prevention, 
2014).   
Risk factors for IPD have been well documented throughout the years.  Both race and age play a 
significant role in contributing to the risk of pneumococcal disease.  Children at an increased risk 
for IPD include those that are younger than two years of age, and those that have certain 
immunosuppressant illnesses (Centers for Disease Control and Prevention, 2015).  Illnesses such 
as sickle cell disease, HIV infection, and chronic heart and lung conditions are considered 
underlying conditions to IPD (Centers for Disease Control and Prevention, 2015).  Adults 65 
years and older are also at a heightened risk.  Other risk factors in adults 19 through 64 years old 
include: chronic conditions (i.e., diabetes and heart disease), HIV/AIDS, cancer, and chronic 
smoking (Baxter, 2016).  Figure 4.1 shows common underlying conditions associated with IPD 
that are present on the ABCs case report forms.  
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In 1977, the first pneumococcal vaccine was licensed in the United States and the first conjugate 
vaccine in 2000.  PCV 13, an inactivated conjugate vaccine, is normally administered to children 
two years of age or younger, to adults 65 years and older, and younger adults ≥ 19 years of age 
with certain immunosuppressant conditions, such as HIV and kidney disease.  PPSV 23, an 
inactivated polysaccharide vaccine, is administered to adults 65 years and older, and to children 
and younger adults ≥ 19 years of age with certain high-risk conditions, such as diabetes and heart 
disease.  Additionally, PCV 13 combines capsular polysaccharides with a protein carrier; PCV 
13 then initiates a T-cell immune response with antibody production (Hayward et al, 2016).  
Likewise, PPSV 23 contains capsular polysaccharide antigens and these antigens produce a T-
cell independent antibody response (Hayward et al, 2016).  With the recommended routine use of 
the pneumococcal conjugate vaccine (PCV 13 or Prevnar 13) and the pneumococcal 
polysaccharide vaccine (PPSV 23 or Pneumovax) rates of IPD have declined from 100 cases per 
100,000 in 1998 to 9 cases per 100,000 in 2015 (Centers for Disease Control and Prevention, 
2015).  Appendix 2 shows the CDC recommendations for pneumococcal vaccinations by age and 
by health condition.  
For this IPD project, I utilized the ABCs 2011-2016 IPD data within REDCap and Access, to 
analyze populations of patients with IPD and high-risk conditions.  Furthermore, the percentages 
of the non-vaccinated were analyzed to provide awareness and knowledge of vaccination gaps.  
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Objective 
The objective of this project was to evaluate ABC’s data from REDCap and Access to identify 
the high-risk conditions of patients with IPD that have not received a pneumococcal vaccine.   
Methods 
Data Collection: 
Invasive pneumococcal disease (IPD) data are collected as part of the ABCs program within the 
TN EIP.  These data were analyzed for high-risk conditions and vaccination records.  The ABCs 
surveillance area consists of 20 counties across Tennessee.  When possible, ABCs cases are 
identified from the hospital labs or diagnostic labs: the surveillance officer (SO) will then 
determine if it meets the appropriate case definition.  An IPD case is defined as a positive culture 
of Streptococcus pneumoniae in an adult (aged ≥ 19 years old) with one or more high-risk 
conditions within the Tennessee catchment areas.  The respective age groups include: Group 1 
(age 19-49), Group 2 (age 50-64), Group 3 (age 65-84), and Group 4 (age 85 and older).  High-
risk conditions include, but are not limited to, AIDS, HIV infection, current smoking, and 
asthma.  The SO will collect medical information from confirmed cases via a standardized case 
report form (CRF).  Appendix 1 shows an example of the ABCs CRF. 
Data Analysis:  
To obtain IPD data for this project, data from 2011-2012 were extracted from Microsoft Access, 
and data from 2013-2016 were extracted from REDCap.  These data included IPD cases in the 
Tennessee catchment areas for adults ≥ 19 years of age with underlying conditions.  All data, 
consisting of 2,693 IPD cases, were then compiled into one excel worksheet.   
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Results 
From 2011-2016, there were 2,693 confirmed IPD cases within the Tennessee catchment area.  
To evaluate the most prevalent underlying conditions among these IPD cases and to also evaluate 
vaccination information, I divided my capstone project into three phases.   
Phase 1: Demographics of Study Population   
During the first phase of my main project, I was able to use descriptive statistics to identify the 
demographic characteristics of my study population.  The demographics evaluated involved: 
gender, age, race, and ethnic origin.  For this study population, the total number of IPD cases, 
2,693, were analyzed to display the basic demographics.  The study population contained 
50.50% females and 49.42% males; the additional percentage is unknown due to lack of CRF 
completion.  The age of the population varied; however, the largest proportion (35.54%) of the 
population was comprised of the 50-64 age group; additional age groups were 19-49, 65-84, and 
85+ years as demonstrated in Figure 4.2.  Figure 4.3 shows that the Caucasian race had the 
highest proportion (69.74%) compared to the additional races (African American, American 
Indian, Asian, Native American/Pacific, Unknown).  Finally, the largest ethnic origin of the 
study population was shown to be Not Hispanic/Latino (74.12%), which is highlighted in Figure 
4.4.  
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Figure 4.2 Age percentages for study population 
 
 
Figure 4.3 Race percentages of study population  
11%
35%
36%
18%
Age
85+
65-84
50-64
19-49
70%
26%
2% 2%
Race
White Black Native Hawaiian/Pacific Unknown
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Figure 4.4 Ethnic Origin percentages of study population 
 
Secondly, the hospital and ICU percentages were analyzed within the study population, which 
was completed by stratifying the age groups and calculating the percentages of hospital and 
Intensive Care Unit (ICU) admissions. While the hospital admission percentages were relatively 
high in all age groups, the age group for the 50-64 year olds had the highest hospital admission 
percentage (99%).  Similarly, the ICU percentages for this age group (48%) were also the highest 
among the age groups.  Figure 4.5 demonstrates the hospital and ICU admission percentages for 
each age group within the study population.  
1%
75%
24%
Ethnic Origin
Hispanic/Latino
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Figure 4.5 Hospital and ICU admission percentages of each age group within the study population 
 
Lastly in phase 1, the underlying conditions for IPD were calculated and identified.  Out of the 
2,693 IPD cases that met case definition, the five most prevalent underlying conditions were 
identified.  The five most prevalent IPD underlying conditions included: ASCVD (16%), 
Diabetes (26%), COPD (29%), Smoking (37%), and other illnesses (19%), which can be seen in 
Figure 4.6.  Other illnesses included: colitis, hepatitis C, hypothyroidism, and other illnesses not 
specified on the case report form.    
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Figure 4.6 Most prevalent Invasive Pneumococcal Disease (IPD) underlying conditions of study 
population 
 
Phase 2: IPD Underlying Conditions  
During the second phase, I continued the use of descriptive statistics and carried out an analysis 
of the most prevalent underlying conditions for each age group.  This was conducted by 
stratifying the age groups via Microsoft Excel.  All ages were stratified into four groups as 
follows: 19-49, 50-64, 65-84, and ≥ 85 years.  These age groups were adjusted so that each group 
contained a larger study population.  The five most prevalent underlying conditions, listed in 
phase 1, were then analyzed for each age group.  For both the youngest age group (19-49) as well 
as the 50-64 age group, the most prevalent underlying condition was smoking (42% and 51%).  
The most frequent condition for the group 65-84 was COPD (39%).  Finally, ASCVD (30%) was 
the most common underlying condition for the oldest age group, ≥ 85.  Figure 4.7 displays the 
most prevalent underlying condition for each age group.  
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Figure 4.7 Most prevalent underlying conditions for each age group in the study population 
 
Phase 3: Pneumococcal Vaccinations   
During the third phase, I analyzed vaccination percentages within each age group. The 
vaccination percentages were highest within the oldest age groups and lowest within the 
youngest age groups, as seen in Figure 4.8.   The CDC recommends the routine vaccinations of 
adults 65 years and older, as well as adults 19 years and older with one or more underlying 
condition (Centers for Disease Control and Prevention, 2015).  Secondly, the vaccination 
percentages for all five underlying conditions within each age group were calculated. This was 
completed by separating each age group into an individual chart and carrying out the vaccination 
percentage calculations for all five conditions.  The results are displayed in Figures 4.9-4.12 
below.  
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Figure 4.9 Vaccination percentages for age group 19-49 within the study population 
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Figure 4.8 Vaccination percentages for each age group within the study population 
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Figure 4.10 Vaccination percentages for age group 50-64 within the study population 
 
 
Figure 4.11 Vaccination percentages for age group 65-84 within the study population 
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Figure 4.12 Vaccination percentages for age group 85+ within the study population 
 
Next, I analyzed the vaccine types (PCV713 and/or PPSV23) for all age groups, 
stratifying them by year (2011-2016), as seen in Figure 4.13.  Following, I evaluated the 
percentages of the vaccinated population that received dual vaccines; results show that less than 
1.7% of the age group, 65-85, and less than 2.2% of the age group, 19-49, received the 
recommended dual vaccines.   Lastly, I analyzed the percentages of vaccine types within each 
age group, for each underlying condition, for each individual year (2011-2016).  Figures 4.14-
4.19 indicate the results based on each year.  
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Figure 4.13 The vaccine types for each age group through the years 2011-2016 
 
 
 
Figure 4.14 The percentage of underlying conditions by vaccine type within each age group for year 
2011  
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Figure 4.15 The percentage of underlying conditions by vaccine type within each age group for year 
2012 
 
 
Figure 4.16 The percentage of underlying conditions by vaccine type within each age group for year 
2013 
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Figure 4.17 The percentage of underlying conditions by vaccine type within each age group for year 
2014 
 
 
Figure 4.18 The percentage of underlying conditions by vaccine type within each age group for year 
2015 
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Figure 4.19 The percentage of underlying conditions by vaccine type within each age group for year 
2016 
Discussion 
Study Analysis: 
The analyses that were conducted for this study shed light on various underlying conditions 
associated with IPD, and also on vaccination gaps within those conditions and certain age 
groups.  The data presented shows that the five most prevalent underlying conditions correlated 
with IPD are as follows: ASCVD, diabetes, COPD, smoking, and other illnesses.  Each age 
group exhibited a distinctive underlying condition, with smoking being the most prevalent in the 
youngest two age groups.  In comparison, the CDC recognizes HIV/AIDs, diabetes, heart/liver 
disease, smoking and asthma as the most prevalent underlying conditions nationally.  
The vaccination percentages among the younger age groups were considerably lower when 
compared to the older age groups.  This was considered to be a possibility due to the ACIP 
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recommendation that adults 65 years and older should be vaccinated for pneumococcal disease, 
and the lack of education relating to vaccination protocol for those with high-risk conditions.  
While the recommendations from CDC include the routine vaccinations of adults 65 years and 
older, as well as adults 19 years and older with specific underlying conditions, this observational 
study portrays that a large proportion of the younger age groups are unvaccinated.  In retrospect, 
vaccination rates in adults are drastically low and show that only 20% of individuals with a high 
risk of pneumonia are vaccinated (Centers for Disease Control and Prevention, MMWR, 2016).  
More so, only 14.2% of adults have received the Tdap vaccine that protects them from tetanus, 
diphtheria, and pertussis (Centers for Disease Control and Prevention, MMWR, 2016).  From 
this, the age groups were separated for analysis of each high-risk condition and the vaccination 
rates within.  For all age groups, it was evident that the majority of patients were unaware of 
their vaccination status, and well over 40% of all high-risk condition patients in the study 
population marked “unknown” for their vaccination status.  Finally, the analysis of vaccination 
types concluded that the most prevalent vaccine in all age groups, from years 2011-2016, was the 
vaccination type PPSV23.  Unfortunately, there was little information established for years 2014 
and 2015, leading to an inaccurate explanation.  The reasoning behind the lack of information 
gathered in the years 2014 and 2015 is unknown.  Additionally, the proportions of those that 
received the recommended both vaccines were extraordinarily low in all age groups.  This was 
surprising given that the ACIP recommends that all adults 65 years of age and older and/or those 
adults with specific underlying conditions follow through with both vaccines.  Recently, there 
are no studies that explain why the dual vaccination rates are low.   
The data presented explains the presence of specific underlying conditions and vaccination gaps 
within certain age groups.  It is apparent that some patients with underlying conditions, and 
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specifically the younger age groups, go unvaccinated.  More so, it is evident that there are low 
percentages of dual vaccinations, which the CDC recommends.  Since the introduction of these 
vaccinations, IPD has drastically declined in all age groups.  Figures 4.22 and 4.23 explain the 
trend of IPD through the years 1998-2015 and how vaccinations have impacted this disease.  It 
can be concluded that the trend of IPD rates declining, in both these specific age and condition 
groups, can and will likely continue if patient education on vaccinations is made a priority by all 
healthcare providers.  
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Figure 4.20 Trends in IPD among adults 19-64 years of age, 1998-2015 
 
 
 
 
  
 
 
32 
 
 
Figure 4.21 Trends in IPD in adults 65 years and older, 1998-2015 
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Vaccination Limitations 
Although the most recent pneumococcal vaccination, PPSV 23, can reduce the chances of IPD 
by 78% and the chances of pneumococcal pneumonia by 82%, ACIP reevaluates these 
recommendations every few years (Hayward et al, 2015).  In 2014, ACIP recommended the 
sequential use of PCV 13 and PPSV 23 due to the concern of the persistent burden in elderly 
adults (Hayward et al, 2015).  This recommendation insists on adults 65 years and older on 
getting vaccinated with one dose of PCV 13 and then one dose of PPSV 23 one year later 
(Centers for Disease Control and Prevention, 2014).  More so, it is important to note that adults 
should only receive one dose of PCV 13, but can receive more than one dose of PPSV 23, 
depending on the age and underlying condition status of the individual (Centers for Disease 
Control and Prevention, 2014).  Unfortunately, research supports that the PPSV 23 vaccination 
efficacy is not as high in adults, 65 years and older, and adults with certain underlying conditions 
(Musher et al, 2015).  This is one motive behind the ACIP recommendation of the dual 
vaccination.   
In this study, IPD prevalence, certain high-risk conditions associated with the illness, and 
vaccination gaps within the study population were analyzed.  As this study population consisted 
of individuals with certain high-risk conditions that were diagnosed with IPD, it is evident that 
some of these individuals were properly vaccinated with PCV 13 and/or PPSV 23.  However, 
this study reveals the significant vaccination gaps and the lack of the recommended dual 
vaccination within the majority of the population.  Although some individuals were properly 
vaccinated with either PCV 13 or PPSV 23, the majority failed to follow the recommendation of 
the dual pneumococcal vaccination, which can explain the high IPD incidence in those that 
received one of the vaccine types.  Although the efficacy of PPSV 23 is lower in adults, 65 years 
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and older, and those adults with certain high-risk conditions, research suggests that use of the 
dual vaccinations can significantly reduce the chances of pneumococcus illness (Musher et al, 
2015).  ACIP will reevaluate these pneumococcal vaccination recommendations in 2018 (Centers 
for Disease Control and Prevention, 2014).    
Study Limitations: 
One limitation of this study is the incompletion of case report forms (CRFs) and 
immunization/vaccination records.  These forms were critical components in the study; however, 
an extensive number was discarded during the study due to incompletion by the patient.  Several 
CRFs were left incomplete by patients or their health care providers due to unknown reasons.  If 
these forms had been completed accurately, it would have allowed for a larger study population.   
Additionally, the lack of communication between healthcare providers and patients was evident.  
A number of CRFs were left unmarked or “unknown” due to the lack of knowledge and 
understanding of what vaccines the patient was receiving or had received in the past.  More so, it 
was understood that several patients, especially in older age groups, had difficulty reading and 
understanding the case report forms they were obligated to fill out.  It is my full belief that 
educating the patient on the administered vaccinations, and assisting them with understanding 
the questions on the CRFs would have greatly increased the number of completed cases for this 
study, which likely would have impacted my findings. 
Future Studies: 
First of all, a larger study population should be incorporated to this study to provide a more 
accurate estimate.  Additionally, the comparison of pneumococcus vaccination rates among all 
ten EIP states would be interesting to evaluate.  Variables, such as hospital/ICU rates, 
vaccination rates, insurance types (Medicare/Medicaid vs. Private), and case fatality rates, 
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among a similar study population could be investigated and later compared to all EIP states.  
Since Tennessee had the highest IPD rates among all EIP sites in 2014, this data could provide 
insight on how the state is improving or not improving on decreasing IPD cases.  
Another possible study could include pregnant women with one or more of the IPD underlying 
conditions and their vaccination rates.  While there are ongoing studies involving the efficacy of 
the vaccination for pregnant women and their infants, it would be compelling to assess their 
specific vaccination rates, since women of childbearing age are significantly younger than the 
current recommended vaccination age.  Finally, a more in depth study to measure the risk of the 
recurrence of IPD within certain underlying conditions could be conducted.  This would allow 
for specific underlying conditions to surface as increased risks for recurrence of disease; 
healthcare providers could better educate patients on their risks of IPD.   
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Chapter 4: Conclusion 
 
My field experience at the Tennessee Emerging Infections Program provided me with an in 
depth knowledge of a variety of public health methods, specifically population based 
surveillance.  It was during my four months at EIP that I became knowledgeable in surveillance 
methods, database management, and other techniques that are used in the public health field.  
Through both my minor projects and my capstone project, I was able to put my acquired 
knowledge to test, and learn and grow from my experience and inexperience. Additionally, being 
able to apply what I learned in the MPH program thus far was exciting.  Applying what I knew 
and adding to that knowledge allowed me to understand my strengths, but also identify the areas 
in which I can improve.   
The SNiPP database entry project gave me a prospective of different software used within public 
health.  I was able to shadow and learn from staff members that worked specifically with these 
databases.  More so, it provided me with the skills necessary to extract medical information from 
case report forms and other medical records.  By entering the negative UATs, the CDC, EIP, and 
local hospitals and clinics will have an in depth understanding of non-invasive pneumococcal 
pneumonia prevalence and diagnostic methods.   
My work with Streptococcus pneumoniae brought awareness to high-risk conditions in multiple 
age groups, vaccination rates, and vaccination gaps among those with certain underlying 
conditions and age groups.  Through this project I was able to learn additional surveillance 
techniques and management of databases.  
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Chapter 5: Core Area Competencies 
Biostatistics  
 This course allowed me to further my understanding of data analysis, which became a 
significant contributor for my major project.  Through my field experience, I relied on the use of 
software, such as Excel, in several activities, and also incorporated descriptive statistics into my 
capstone project.  
Environmental Health  
 This course allowed me to acknowledge the link between disease prevalence and our 
environment.  While extracting medical information from patient records, I was able to identify 
that some illnesses resulted from the patient’s environment (i.e. occupation) and not necessarily 
their behaviors or genetics.  I was able to recognize occupational illnesses, such as 
Mesothelioma, that were associated with a few CRF’s within my study.  
Epidemiology 
 This course gave me an exceptional amount of information that contributed to my 
understanding and participation in disease surveillance.  During my major project, I was able to 
efficiently and effectively set up a design plan and protocol for my study.  More so, I was able to 
identify risk factors and vaccination gaps associated with the specific disease.  
Health Service Administration 
 This course allowed me to have an accurate understanding of our health care system.  As 
I extracted information from medical records and case report forms, I recalled the rules and 
regulations, such as HIPAA, that ensure the patient’s confidentiality.  My understanding of 
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health insurance, more specifically Medicare and Medicaid, allowed me to have a better 
understanding of a patient’s care services, and also aided in numerous surveillance studies.  
Social and Behavioral Science   
 This course gave me an increased understanding of high-risk behaviors and conditions, 
and also how our demographics play a key role in our health and health services.  Through my 
field experience, I was able to acknowledge the health disparities that are common in our health 
care system.  Additionally, I had the opportunity to recognize that certain behaviors and 
conditions in society reflect back to our own health. 
 
 
 
 
 
 
 
 
  
  
 
 
39 
Bibliography 
Baxter, R., Lee, A., Aukes, L., Snow, V., Fireman, B., Atkinson, B., Klein, N. (2016) Risk of 
Underlying Chronic Medical Conditions for Invasive Pneumococcal Disease in Adults. 
Vaccine. 34(36), (4293-4297).  
Centers for Disease Control and Prevention. (1994). Addressing Emerging Infectious Disease 
Threats: a prevention strategy for the United States. Executive Summary. MMWR 
 Recomm Rep, 1-18.  
Centers for Disease Control and Prevention. (2015). Pneumococcal Disease: About 
Pneumococcal. Retrieved May 1, 2017, from 
http://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html. 
Centers for Disease Control and Prevention (2010). Updates Recommendations for Prevention of 
Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal 
 Polysaccharide Vaccine (PPSV23). Retreived June 25, 2017, from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm. 
Centers for Disease Control and Prevention (2014). Manual for the Surveillance of Vaccine-
Preventable Diseases. Retrieved June 20, 2017 from 
https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html 
Couturier, M R, et al. “Urine antigen tests for the diagnosis of respiratory infections: 
legionellosis, histoplasmosis, pneumococcal pneumonia.” Clinics in laboratory 
medicine., U.S. National Library of Medicine, June 2014, 
www.ncbi.nlm.nih.gov/pubmed/24856525. Accessed 27 Sept. 2017. 
Hayward, Starla, et al. “Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined 
With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 
Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ.” 
Journal of Patient-Centered Research and Reviews, vol. 3, no. 2, 2016, pp. 111–115., 
doi:10.17294/2330-0698.1214. 
Henriques-Normark, Birgitta, and Elaine I. Tuomanen. "The Pneumococcus: Epidemiology, 
Microbiology, and Pathogenesis." Cold Spring Harbor Perspectives in Medicine. Cold 
Spring Harbor Laboratory Press, July 2013. Web. 08 Aug. 2017. 
Mccullers, J. A. “Insights into the Interaction between Influenza Virus and Pneumococcus.” 
Clinical Microbiology Reviews, vol. 19, no. 3, Jan. 2006, pp. 571–582., 
doi:10.1128/cmr.00058-05. 
Musher, Daniel M., and Maria B. Rodriguez-Barradas. “Why the recent ACIP recommendations 
regarding conjugate pneumococcal vaccine in adults may be irrelevant.” Human Vaccines 
& Immunotherapeutics, vol. 12, no. 2, 2015, pp. 331–335., 
doi:10.1080/21645515.2015.1098794. 
Tennessee Department of Health (2017). Emerging Infections Programs, (1-4). Retrieved May 1, 
2017, from http://www.tn.gov/health/article/emerging-infections-programs. 
 
  
 
 
40 
Appendix 1
 
 
  
 
 
41 
 
  
 
 
42 
Appendix 2 
 
 
  
 
 
43 
 
  
 
 
44 
 
